Siegfried : confirmed in the Dow Jones Sustainability Index Europe for the second consecutive year
December 15, 2022 at 05:32 pm
Share
Media Release
Zofingen, 15 December 2022
Siegfried confirmed in the Dow Jones Sustainability Index Europe for the second consecutive year
Siegfried is proud to announce that it has been confirmed as a member of the Dow Jones Sustainability Index (DJSI) Europe for the second consecutive year. The DJSI is a widely recognized standard for measuring corporate environmental, social, and governance (ESG) progress across industries. Siegfried is currently the only CDMO (Contract Development and Manufacturing Organization) in the DJSI Europe.
Luca Dalla Torre, General Counsel and Chairman of the Siegfried Sustainability Board:
"We are delighted to be recognized as a sustainability leader. The confirmed membership in the DJSI Europe is the result of our commitment and continuous efforts in the various areas of sustainability. Sustainability is one of our five core values and is an important element of Siegfried's long-term strategy."
To learn more about our sustainability initiatives, please read Siegfried's Sustainability Report 2021and visit https://www.siegfried.ch/sustainability.
Contact
Media:
Financial Analysts:
Peter Stierli
Dr. Reto Suter
Head Corporate Communications
Chief Financial Officer
Tel. +41 62 746 15 51
Tel. +41 62 746 11 35
peter.stierli@siegfried.ch
reto.suter@siegfried.ch
Siegfried Holding AG
Untere Bruehlstrasse 4
CH-4800 Zofingen
This media release on the web
www.siegfried.ch/media-releases
1
About Siegfried
The Siegfried Group is a global life sciences company with a network of 11 sites in Europe, the USA and Asia. Siegfried offers contract developing and manufacturing of pharmaceutical APIs, intermediates, as well as drug products. In 2021, Siegfried achieved sales of 1.1 billion Swiss francs and more than 3'600 employees. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).
2
Attachments
Original Link
Original Document
Permalink
Disclaimer
Siegfried Holding AG published this content on 15 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 December 2022 17:32:04 UTC.
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.